RxDoctor Payments Data

Susan Daniel, APRN

Family · Owensboro, KYNPI 1942486014

Payments from drug & device makers

$1,733in general payments, 2019–2025

Across 96 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$361
  • Novo Nordisk$213
  • Gilead$174
  • AbbVie$170
  • Abbott$131
  • AstraZeneca$104
  • plus $580 from 16 others

What the payments were for

  • Food & beverage$1,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,733 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$30,362
Medicare patients
110
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$92,711
JanuviaSitagliptin Phosphate98$80,797
TrulicityDulaglutide31$36,430
EliquisApixaban43$31,614
TradjentaLinagliptin38$25,320
MounjaroTirzepatide21$23,485
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog50$22,921
JardianceEmpagliflozin26$21,790
RybelsusSemaglutide16$18,718
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$16,316
FarxigaDapagliflozin Propanediol12$14,509
MyrbetriqMirabegron20$12,170
Breo ElliptaFluticasone/Vilanterol22$9,628
SymbicortBudesonide/Formoterol Fumarate24$7,959
Albuterol Sulfate HfaAlbuterol Sulfate203$6,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$213$111,429106 claims
Lilly USA, LLCTrulicity, Mounjaro$361$59,91552 claims
Boehringer IngelheimTradjenta, Jardiance$103$47,11064 claims
PfizerEliquis$42$31,61443 claims
AstraZenecaFarxiga, Symbicort$104$22,46836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →